260 related articles for article (PubMed ID: 23103087)
21. An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma.
Popat R; Khan I; Dickson J; Cheesman S; Smith D; D'Sa S; Rabin N; Yong K
Br J Haematol; 2015 Jan; 168(1):148-51. PubMed ID: 25103844
[No Abstract] [Full Text] [Related]
22. Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Grandoni F; Stalder G; Borgeat Kaeser A; Ribi C; Cairoli A; Blum S
Leuk Lymphoma; 2019 Dec; 60(12):3087-3089. PubMed ID: 31161829
[No Abstract] [Full Text] [Related]
23. Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Mangiacavalli S; Albani G; Caravita T; Cocito F; Pascutto C; Zappasodi P; Bringhen S; Palumbo A; Cazzola M; Corso A
Leuk Lymphoma; 2012 Mar; 53(3):514-5. PubMed ID: 22141736
[No Abstract] [Full Text] [Related]
24. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
25. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Thornburg A; Abonour R; Smith P; Knox K; Twigg HL
Chest; 2007 May; 131(5):1572-4. PubMed ID: 17494808
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Jena RK; Swain TR; Kansurkar SS; Swain M
Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
[TBL] [Abstract][Full Text] [Related]
28. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
[No Abstract] [Full Text] [Related]
29. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
30. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
31. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E
Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988
[TBL] [Abstract][Full Text] [Related]
33. [Experience of using thalidomide in the treatment of patients with multiple myeloma].
Novosad OI; Kriachok IA; Kadnikova TV; Tytorenko IB; Sychova TV; Kostiukova NI
Lik Sprava; 2010; (3-4):79-86. PubMed ID: 21265124
[TBL] [Abstract][Full Text] [Related]
34. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
35. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Bonkowski J; Vermeulen LC; Kolesar JM
J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
[TBL] [Abstract][Full Text] [Related]
36. Is Maintenance Therapy for Everyone?
Nooka AK; Lonial S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S139-44. PubMed ID: 27521311
[TBL] [Abstract][Full Text] [Related]
37. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide: second cancers.
Prescrire Int; 2012 May; 21(127):130. PubMed ID: 22844687
[No Abstract] [Full Text] [Related]
39. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
Pretz J; Medeiros BC
Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102
[No Abstract] [Full Text] [Related]
40. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]